Date: 2015-01-05
Type of information: Company acquisition
Acquired company: Redvax (Switzerland)
Acquiring company: Pfizer (USA - NY)
Amount: undisclosed
Terms: * On January 5, 2015, Pfizer announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren.
Details: This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program. The CMV vaccine program will complement Pfizer’s research portfolio of high-quality and life-saving investigational vaccines and place Pfizer among the leaders in CMV research and development.
Related: Vaccines Infectious diseases
